Abstract: Renal cell carcinoma （RCC） is one of the most common malignant tumors of the urinary system, with metastatic dissemination occurring  at substantial frequencies.  This malignancy demonstrates limited sensitivity to chemotherapy drugs and conventional radiotherapy, and the current treatment for advanced⁃stage RCC primarily relies on targeted therapy and immunotherapy. Emerging evidence indicates that RCC does not show strong resistance to hypofractionated radiotherapy, as evidenced by significantly diminished tumor cell viability when single⁃fraction doses escalate to 6 Gy. In recent years, stereotactic body radiation therapy has been widely used in the local disease control for advanced RCC, capitalizing on to its characteristics of ablative fractional dose, high precision, and non⁃invasiveness, demonstrates an excellent local tumor control rate of the lesion with acceptable reaction. This article reviews the progress in the application of stereotactic body radiation therapy in oligometastatic and oligoprogressive  RCC.

Key words: Stereotactic body radiation therapy, Renal cell carcinoma, Oligometastatic； Oligoprogressive； Targeted therapy, Immunotherapy